We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ProImmune Receives GLP Accreditation for Cell-Mediated Immune Response Assay Services
News

ProImmune Receives GLP Accreditation for Cell-Mediated Immune Response Assay Services

ProImmune Receives GLP Accreditation for Cell-Mediated Immune Response Assay Services
News

ProImmune Receives GLP Accreditation for Cell-Mediated Immune Response Assay Services

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ProImmune Receives GLP Accreditation for Cell-Mediated Immune Response Assay Services"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The accreditation will enable pharmaceutical and biotech companies worldwide to seamlessly incorporate ProImmune’s GLP, as well as GCP (Good Clinical Practice), compliant services, such as cell-mediated immunity assays, into their preclinical and clinical development programs, with the confidence that the data will fully meet the different international regulatory submission requirements.

During the development of biological therapies, assays that reliably measure cellular immune responses are vital in examining the safety and efficacy profiles of the potential therapeutic. Cell-mediated immune response assays are notoriously difficult, time consuming and costly to implement in-house, therefore having access to ProImmune’s GLP and GCP compliant assays provides an outsourcing solution for developers of novel therapies.

Dr Nikolai Schwabe, CEO of ProImmune, said: “We are committed to supporting our global customers’ requirement for understanding and characterizing immune responses during all phases of pharmaceutical product development, including immunogenicity risk assessment and vaccine optimization and development. Obtaining GLP and GCP accreditation demonstrates that our services are consistently performing at a high standard in a regulated environment.”

Advertisement